VERO Biotech
2 known investors
VERO Biotech develops next-generation inhaled nitric oxide (iNO) delivery systems for patients with cardiopulmonary conditions in acute care hospital settings. The company focuses on designing and commercializing innovative medical devices to address unmet clinical needs.
BiotechHealthtechMedical Devices
Investors · 2
Competitors · 2
by search overlap
Vero Bioscience14 shared keywordsVero BioScience develops a blood-based proteomic test that measures organ-specific protein signatures to assess the biological age of individual organs and detect early signs of age-related disease. The company targets individuals seeking predictive health insights and preventive medicine interventions based on technology developed at Stanford.
Preqin13 shared keywordsPreqin provides private markets data, analytics, and benchmarking across private equity, venture capital, hedge funds, real estate, private credit, infrastructure, secondaries, and natural resources. Its products serve fund managers, investors, consultants, banks, and other financial professionals for fundraising, manager selection, due diligence, and performance analysis.
Companies competing with VERO Biotech for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does VERO Biotech do?
- VERO Biotech develops next-generation inhaled nitric oxide (iNO) delivery systems for patients with cardiopulmonary conditions in acute care hospital settings. The company focuses on designing and commercializing innovative medical devices to address unmet clinical needs.
- Who are VERO Biotech's investors?
- VERO Biotech's investors include Brace Pharma, Runway Growth Capital.